From the natural evolution to the genetic manipulation of the host-range of retroviruses

Biological Chemistry

Volumn 378, Issue 6, 1997, Pages 457-468

  Dornburg, Ralph ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

AIDS; Cancer; Gene therapy; Genetic diseases; Retroviral vectors

Indexed keywords

ENVELOPE PROTEIN; RNA POLYMERASE; VIRUS GLYCOPROTEIN;

ENVELOPE GENE; EVOLUTION; GENE THERAPY; GENE TRANSFER; GENETIC MANIPULATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; RETROPOSON; RETROVIRUS; REVIEW; VIRAL GENETICS; VIRUS CELL INTERACTION; VIRUS RECOMBINATION;

ANIMALS; EVOLUTION, MOLECULAR; GENE PRODUCTS, ENV; GENETIC ENGINEERING; HUMANS; RETROVIRIDAE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; UNIDENTIFIED RETROVIRUS;

EID: 0030852172     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Altaner, C. (1995). Gene therapy for cancer (present status). Neoplasma 42, 209-213.
2. Bird, R.E., Hardman, K.D., Jacobson, J.W., Johnson, S., Kaufmann, B.M., Lee, S.-M., Lee, T., Pope, S.H., Riordan, G.S., and Whitlow, M. (1988). Single-chain antigen-binding proteins. Science 242, 423-426.
3. Blaese, R.M. (1995). Steps toward gene therapy: 1. the initial trials. Hosp Pract (Off Ed) 30, 33-40.
4. Boris-Lawrie, K., and Temin, H.M. (1994). The retroviral vector replication cycle and safety considerations for retrovirus-mediated gene therapy. Ann. N.Y. Acad. Sci. 716, 59-70.
5. Brodsky, I., Foley, B., and Gillespie, D. (1993). Expression of human endogenous retrovirus (herv-k) in chronic myeloid leukemia. Leuk. Lymphoma 11, Suppl. 1, 119-123.
6. Brookfield, J.F. (1995). Molecular evolution retroposon revivals. Curr. Biol. 5, 255-256.
7. Cai, Q., Rubin, J.T., and Lotze, M.T. (1995). Genetically marking human cells-results of the first clinical gene transfer studies. Cancer Gene Ther 2, 125-136.
8. Casella, C., and Panganiban, A.T. (1993). The matrix region is responsible for the differential ability of two retroviruses to function as helpers for vector propagation. Virology 192, 458-464.
9. Chu, T.-H., Martinez, I., Sheay, W.C., and Dornburg, R. (1994). Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins. Gene. Ther. 1, 292-299.
10. Chu, T.-H., and Dornburg, R. (1995). Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer. J. Virol. 69, 2659-2663.
11. Chu, T.-H., and Dornburg, R. (1997). Towards highly-efficient cell-type-specific gene transfer with retroviral vectors that display a single chain antibody. J. Virol. 71, 720-725. (In press)
12. Coffin, J.M. (1992). Genetic diversity and evolution of retroviruses. Curr. Top. Microbiol. Immunol. 176, 143-164.
13. Cosset, F.-L., Morling, F.J., Takeuchi, Y., Weiss, R.A., Collins, M.K.L., and Russell, S.J. (1995). Retroviral retargeting by envelopes expressing an N-terminal binding domain. J. Virol. 69, 6314-6322.
14. Cosset, F-L., and Russell, S.J. (1996). Targeting retrovirus entry. Gene Ther. 3, 946-956.
15. Cournoyer, D., and Caskey, C.T. (1993). Gene therapy of the immune system. Annu. Rev. Immunol. 11, 297-329.
16. Culver, K.W. (1996). Measuring success in clinical gene therapy research. Mol. Med. Today 2, 234-236.
17. Donahue, R.E., Kessler, S.W., Bodine, D., McDonagh, K., Dunbar, C., Goodman, S., Agricola, B., Byrne, E., Raffeld, M., Moen, R., and et al. (1992). Helper virus induced T cell lymphoma in non-human primates after retroviral mediated gene transfer. J. Exp. Med. 176, 1125-1135.
18. Doolittle, R.F., Feng, D.F., Johnson, M.S., and McClure, M.A. (1989). Origins and evolutionary relationships of retroviruses. Q. Rev. Biol. 64, 1-30.
19. Doolittle, R.F., Feng, D.F., McClure, M.A., and Johnson, M.S. (1990). Retrovirus phylogeny and evolution. Curr. Top Microbiol. Immunol. 157, 1-18.
20. Doolittle, R.F., and Feng, D.F. (1992). Tracing the origin of retroviruses. Curr. Top Microbiol. Immunol. 176, 195-211.
21. Dornburg, R., and Temin, H.M. (1988). Retroviral vector system for the study of cDNA gene formation. Mol. Cell Biol. 8, 2328-2334.
22. Dornburg, R., and Temin, H.M. (1990a). Presence of a retroviral encapsidation sequence in nonretroviral RNA increases the efficiency of formation of cDNA genes. J. Virol. 64, 886-889.
23. Dornburg, R., and Temin, H.M. (1990b). cDNA genes formed after infection with retroviral vector particles lack the hallmarks of natural processed pseudogenes. Mol. Cell Biol. 10, 68-74.
24. Dornburg, R. (1995). Reticuloendotheliosis viruses and derived vectors. Gene Ther. 2, 301-310.
25. Eckert, K.A., and Kunkel, T.A. (1990). High fidelity DNA synthesis by the Thermus aquaticus DNA polymerase. Nucl. Acid Res. 18, 3739-3744.
26. Emi, N., Friedmann, T., and Yee, J.-K. (1991). Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus. J. Virol. 65, 1202-1207.
27. Essex, M., Matsuda, Z., Yu, X., and Lee, T.H. (1995). Gene therapy against retroviral diseases. Leukemia 9, Suppl. 1, S71-S74.
28. Etienne-Julan, M., Roux, P., Carillo, S., Jeanteur, P., and Piechaczyk, M. (1992). The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker. J. Gen. Virol. 73, 3251-3255.
29. Finnegan, D.J. (1994). Retroviruses and transposons wandering retroviruses? Curr. Biol. 4, 641-643.
30. Flavell, A.J. (1995). Retroelements, reverse transcriptase and evolution, [review]. Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 110, 3-15.
31. Freed, E.O., and Martin, M.A. (1995). The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J. Biol. Chem. 270, 23883-23886.
32. Friedmann, T., and Yee, J.K. (1995). Pseudotyped retroviral vectors for studies of human gene therapy, [review]. Nature Medicine 1, 275-277.
33. Gilboa, E. (1990). Retroviral gene transfer: applications to human gene therapy. Prog. Clin. Biol. Res. 352, 301-311.
34. Goud, B., Legrain, P., and Buttin, G. (1985). Antibody-mediated binding of a murine ecotropic Moloney retroviral vector to human cells allows internalization but not the establishment of the proviral state. Virology 163, 251-254.
35. Han, X.L., Kasahara, N., and Kan, Y.W. (1995). Ligand-directed retroviral targeting of human breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 92, 9747-9751.
36. Herrmann, F. (1996). Clinical application of gene transfer. J. Mol. Med. 74, 213-221.
37. Hoogerbrugge, P.M., von Beusechem, V.W., Kaptein, L.C., Einerhand, M.P., and Valerio, D. (1995). Gene therapy for adenosine deaminase deficiency. Br. Med. Bull. 51, 72-81.
38. Hu, S., Bruszewski, J., Nicolson, M., Tseng, J., Hsu, R.Y., and Bosselman, R. (1987). Generation of competent virus in the REV helper cell line C3. Virology. 159, 446-449.
39. Hu, W.-S., and Temin, H.M. (1990a). Genetic consequences of packaging two RNA genomes in one retroviral particle: pseudodiploidy and high rate of genetic recombination. Proc. Natl. Acad. Sci. USA 87, 1556-1560.
40. Hu, W.-S., and Temin, H.M. (1990b). Retroviral recombination and reverse transcription. Science 250, 1227-1233.
41. Hull, R., and Will, H. (1989). Molecular biology of viral and nonviral retroelements [see comments]. Trends Genet 5, 357-359.
42. Hunter, E., and Swanstrom, R. (1990). Retrovirus envelope glyco-proteins Curr. Top. Microbiol. Immunol. 157, 187-253.
43. Isfort, R.J., Witter, R., and Kung, H.J. (1994). Retrovirus insertion into herpesviruses. Trends Microbiol. 2, 174-177.
44. Johann, S.V., Gibbons, J.J., and O'Hara, B. (1992). Glvr1, a receptor for gibbon ape leukemia virus, is homologous to a phosphate permease of neurospora crassa and is expressed at high levels in the brain and thymus. J. Virol. 66, 1635-1640.
45. Julias, J.G., Hash, D., and Pathak, V.K. (1995). E-vectors: development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy. J. Virol. 69, 6839-6846.
46. Kabat, D. (1995). Targeting retroviral particles to specific cells. Science 269, 417.
47. Kasahara, N., Dozy, A.M., and Kan, Y.W. (1994). Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266, 1373-1376.
48. Katz, R.A., and Skalka, A.M. (1990). Generation of diversity in retroviruses. Annu. Rev. Genet. 24, 409-445.
49. Kawai, S., and Nishizawa, M. (1984). New procedure for DNA transfection with polycation and dimethyl sulfoxide. Mol. Cell Biol. 4, 1172-1174.
50. Ledley, F.D., Brody, B., Kozinetz, C.A., and Mize, S.G. (1992).The challenge of follow-up for clinical trials of somatic gene therapy. Hum. Gene. Ther. 3, 657-663.
51. Ledley, F.D. (1993). Are contemporary methods for somatic gene therapy suitable for clinical applications? Clin. Invest. Med. 16, 78-88.
52. Leib-Mosch, C., Bachmann, M., Brack-Werner, R., Werner, T., Erfle, V., and Hehlmann, R. (1992). Expression and biological significance of human endogenous retroviral sequences. Leukemia 6, Suppl. 3, 72S-75S.
53. Linial, M. (1987). Creation of a processed pseudogene by retroviral infection. Cell 49, 93-102.
54. Lower, R., Lower, J., and Kurth, R. (1996). The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proc. Natl. Acad. Sci. USA 93, 5177-5184.
55. Marin, M., Noel, D., Valsesia-Wittman, S., Brockly, F., Etienne-Julan, M., Russell, S., Cosset, F.-L., and Piechaczyk, M. (1996). Targeted infection of human cells via major histocompatibility complex class I molecules by Moleney leukemia virus-derived viruses displaying single chain antibody fragment-envelope fusion proteins. J. Virol. 70, 2957-2962.
56. Martinez, I., and Dornburg, R. (1995). Mapping of receptor binding domains in the envelope protein of spleen necrosis virus. J. Virol. 69, 4339-4346.
57. Martinez, I., and Dornburg, R. (1996a). Mutational analysis of the envelope protein of spleen necrosis virus. J. Virol. 70, 6036-6043.
58. Martinez, I., and Dornburg, R. (1996b). Partial reconstitution of a replication-competent retrovirus in helper cells with partial overlaps between vector and helper cell genomes. Hum. Gene Ther. 7, 705-712.
59. Matano, T., Odawara, T., Iwamoto, A., and Yoshikura, H. (1995). Targeted infection of a retrovirus bearing a cd4-env chimera into human cells expressing human immunodeficiency virus type 1. Journal of General Virology 76, 3165-3169.
60. Miller, A.D. (1990). Retrovirus packaging cells. Hum. Gene. Ther. 1, 5-14.
61. Miller, A.D., Bonham, L., Alfano, J., Kiem, H.P., Reynolds, T., and Wolgamot, G. (1996). A novel murine retrovirus identified during testing for helper virus in human gene transfer trials. J. Virol. 70, 1804-1809.
62. Mullen, C.A., and Blaese, R.M. (1996). Gene therapy of cancer. Cancer Chemother. Biol. Response Modif. 16, 285-294.
63. Neda, H., Wu, C., and Wu, G. (1991). Chemical modification of an ecotropic murine leukemia virus results in redirection of its target cell specificity. J. Biol. Chem. 266, 14143-14149.
64. Nilson, B.H.K., Morling, F.J., Cosset, F.-L., and Russell, S.J. (1996). Targeting of retroviral vectors through protease-substrate interactions. Gene Ther. 3, 280-286.
65. Nouvel, P. (1994). The mammalian genome shaping activity of reverse transcriptase. Genetica 93, 191-201.
66. Otto, E., Jones-Trower, A., Vanin, E., Stambaugh, K., Mueller, S.N., Anderson, W.F., and McGarrity, G.J. (1994). Characterization of a replication-competent retrovirus resulting from recombination packaging and vector sequences. Hum. Gene Ther. 5, 567-575.
67. Pappas, M.G. (1996). The biotechnology of gene therapy. Drug Development & Industrial Pharmacy 22, 791-803.
68. Parmiani, G., and Colombo, M.P. (1995). Somatic gene therapy of human melanoma: preclinical studies and early clinical trials. Melanoma Res. 5, 295-301.
69. Pathak, V.K., and Temin, H.M. (1990). Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: deletions and deletions with insertions. Proc. Natl. Acad. Sci. USA 87, 6024-6028.
70. Pomerantz, R.J., and Trono, D. (1995). Genetic therapies for HIV infections: promise for the future. AIDS 9, 985-993.
71. Pulsinelli, G.A., and Temin, H.M. (1991). Characterization of large deletions occuring during a single round of retrovirus vector replication: novel deletion mechanism involving errors in strand transfer. J. Virol. 65, 4768-4797.
72. Purcell, D.F., Broscius, C.M., Vanin, E.F., Buckler, C.E., Nienhuis, A.W., and Martin, M.A. (1996). An array of murine leukemia virus-related elements is transmitted and expressed in a primate recipient of retroviral gene transfer. J. Virol. 70, 887-897.
73. Qazilbash, M., Young, N., and Liu, J. (1996). Vectors and target cells for gene therapy of blood diseases. Trends in Cardiovascular Medicine 6, 25-30.
74. Robins, D.M., and Samuelson, L.C. (1992). Retrotransposons and the evolution of mammalian gene expression. Genetica 86, 191-201.
75. Roux, P., Jeanteur, P., and Piechaczyk, M. (1989). A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application to the infection of human by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses. Proc. Natl. Acad. Sci. USA 86, 9079-9083.
76. Russell, S.J., Hawkins, R.E., and Winter, G. (1993). Retroviral vectors displaying functional antibody fragments. Nucl. Acid. Res. 21, 1081-1085.
77. Schnierle, B.S., Moritz, D., Jeschke, M., and Groner, B. (1996). Expression of chimeric envelope proteins in helper cell lines and integration into Moloney murine leukemia virus particles. Gene Ther. 3, 334-342.
78. Shimotohno, K., Mizutani, S., and Temin, H.M. (1980). Sequence of retrovirus provirus resembles that of bacterial transposable elements. Nature 19, 285, 550-554.
79. Somia, N.V., Zoppe, M., and Verma, I.M. (1995). Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc. Natl. Acad. Sci. USA 92, 7570-7574.
80. Tani, K., Lin, T., Hibino, H., Takahashi, K., Nakazaki, Y., Takahashi, S., Nagayama, H., Ozawa, K., Saitoh, I., Mulligan, R., and et al. (1995). Transduction of lacz gene into leukemia cells using viral vectors of retrovirus and adenovirus. Leukemia 9, Suppl. 1, S64-S65.
81. Temin, H.M. (1971). The protovirus hypothesis: speculations on the significance of rna-directed dna synthesis for normal development and for carcinogenesis. J. Natl. Cancer Inst. 46, 3-7.
82. Temin, H.M. (1990). Safety considerations in somatic gene therapy of human disease with retrovirus vectors. Hum. Gene Ther. 1, 111-123.
83. Temin, H.M. (1991). Sex and recombination in retroviruses. Trends Genet 7, 71-74.
84. Temin, H.M. (1993). Retrovirus variation and reverse transcription: abnormal strand transfers result in retrovirus genetic variation. Proc. Natl. Acad. Sci. USA 90, 6900-6903.
85. Tonjes, R.R., Lower, R., Boller, K., Denner, J., Hasenmaier, B., Kirsch, H., Konig, H., Korbmacher, C., Limbach, C., Lugert, R., Phelps, R.C., Scherer, J., Thelen, K., Lower, J., and Kurth, R. (1996). Herv-k: the biologically most active human endogenous retrovirus family. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 13, Suppl. 1, S261-S267.
86. Trono, D. (1994). Molecular biology of HIV. Clinics in Laboratory Medicine 14, 203-220.
87. Uckun, F.M. (1996). Severe combined immunodeficient mouse models of human leukemia. Blood 88, 1135-1146.
88. Urnovitz, H.B., and Murphy, W.H. (1996). Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease. Clin. Microbiol. Rev. 9, 72-99.
89. Valsesia-Wittmann, S., Drynda, A., Deleage, G., Aumailley, M., Heard, J.M., Danos, O., Verdier, G., and Cosset, F.L. (1994). Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J. Virol. 68, 4609-4619.
90. Valsesia-Wittmann, S., Morling, F., Nilson, B., Takeuchi, Y., Russell, S., and Cosset, F.-L. (1996). Improvement of retroviral retargeting by using acid spacers between an additional binding domain and the N terminus of Moloney leukemia virus SU. J. Virol. 70, 2059-2064.
91. Vanin, E.F., Kaloss, M., Broscius, C., and Nienhuis, A.W. (1994). Characterization of replication-competent retroviruses from nonhuman primates with virus-induced t-cell lymphomas and observations regarding the mechanism of oncogenesis. J. Virol. 68, 4241-4250.
92. Varmus, H.E., and Brown, P. (1988). Retroviruses. In: Mobile DNA, D.E. Berg and M.M. Howe, eds. (Washington, D.C.: American Society for Microbiology), pp. 53-108.
93. Weiner, A.M., and Maizels, N. (1994). Molecular evolution, unlocking the secrets of retroviral evolution. Curr. Biol. 4, 560-563.
94. Weis, R., Teich, N., Varmus, H.E., and Coffin, J.M. (1985). RNA Tumor Viruses (Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press).
95. Weiss, R.A. (1993). Cellular receptors and viral glycoproteins involved in retrovirus entry. In: The Retroviridae, J.A. Levy, eds. (New York: Plenum Press), pp. 1-108.
96. Weiss, R.A., and Tailor, C.S. (1995). Retrovirus receptors. Cell 82, 531-533.
97. Whitcomb, J.M., and Hughes, S.H. (1992). Retroviral reverse transcription and integration: progress and problems. Annu. Rev. Cell Biol. 8, 275-306.
98. Whitlow, M., and Filpula, D. (1991). Single-chain Fv proteins and their fusion proteins. Methods Enzymol. 2, 1-9.
99. Williams, K.J., and Loeb, L.A. (1992). Retroviral reverse transcriptases: error frequencies and mutagenesis. Curr. Top. Microbiol. Immunol. 176, 165-180.
100. Wilson, C., Reitz, M.S., Okayama, H., and Eiden, M. (1989). Formation of hybrid virions with gibbon ape leukemia virus and human T-cell leukemia virus retroviral envelope glycoproteins and the gag and pol proteins of moloney leukemia virus. J. Virol. 63, 2374-2378.
101. Young, J.A.T., Bates, P., Willert, K., and Varmus, H.E. (1990). Efficient incorporation of human CD4 protein into avian leukosis virus particles. Science 250, 1421-1423.